# Megan McGill

> Megan McGill, M.D., Ph.D., is the chief executive officer and a board member of Brenig Therapeutics, a clinical-stage neuroscience biotech using an AI-based discovery platform to build small-molecule treatments for neurodegenerative disease. She took the role on October 30, 2025, to steer Brenig's lead Parkinson's program, the LRRK2 inhibitor BT-267, through early human trials. Trained in MRI physics and neuroimaging at NYU and in radiology at Memorial Sloan Kettering, she traded the reading room for the boardroom, building a decade-long run that spans McKinsey consulting, business development at BridgeBio and Regenxbio, and the CEO seat at Epitor, Regel, and HitchBio.

- **Role:** Chief Executive Officer & Board Member at Brenig Therapeutics
- **Organizations:** Brenig Therapeutics, Epitor Therapeutics, Regel Therapeutics, HitchBio, BridgeBio, Regenxbio, McKinsey & Co., Memorial Sloan Kettering Cancer Center, NYU School of Medicine
- **Nationality:** American
- **Education:** M.D. and Ph.D. in neuroimaging and MRI physics, New York University School of Medicine, Radiology residency training, Memorial Sloan Kettering Cancer Center, Radiology residency training, NYU Radiology
- **Known for:** Earned both M.D. and Ph.D. in neuroimaging and MRI physics from NYU School of Medicine, Completed radiology residency training at Memorial Sloan Kettering Cancer Center and NYU, Held the CEO seat at three biotech companies: Epitor Therapeutics, Regel Therapeutics, and HitchBio

## Career timeline

- **—** — Management consultant at McKinsey & Co.
- **—** — Business development and strategy roles at BridgeBio and Regenxbio
- **—** — CEO of HitchBio
- **—** — CEO of Regel Therapeutics
- **—** — CEO of Epitor Therapeutics
- **2025** — Named CEO and board member of Brenig Therapeutics (October 30, 2025)

## Achievements

- Earned both M.D. and Ph.D. in neuroimaging and MRI physics from NYU School of Medicine
- Completed radiology residency training at Memorial Sloan Kettering Cancer Center and NYU
- Held the CEO seat at three biotech companies: Epitor Therapeutics, Regel Therapeutics, and HitchBio
- Appointed CEO and board member of Brenig Therapeutics in October 2025
- Charged with advancing BT-267, a best-in-class LRRK2 inhibitor, into human clinical trials

## Latest updates

- **2025-10** — Named Chief Executive Officer and board member of Brenig Therapeutics on October 30, 2025.
- **2026-02** — Brenig expecting Phase 1 topline data for BT-267 by Q2 2026, with proof-of-concept studies slated to begin by end of 2026.

## Links

- Website: https://brenigther.com
- LinkedIn: http://www.linkedin.com/in/mcgillmegan

---

Profile page: https://yespress.io/megan-mcgill
Published by YesPress — https://yespress.io
Last updated: 2026-06-10